Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986121 | 0.86 | SMN1; SMN2 (0.45) | MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL146771 | 0.85 | MTNR1A (0.55) | MTNR1AMTNR1BCYP19A1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL30185866 | 0.83 | MTNR1A (0.53) | MTNR1AMTNR1BCYP19A1SLC6A2SLC6A4 | |
| SCHEMBL28696042 | 0.83 | MTNR1A (0.53) | MTNR1AMTNR1BCYP19A1SLC6A2SLC6A4 | |
| SCHEMBL3031215 | 0.83 | TAAR1 (0.43) | TAAR1 | |
| SCHEMBL2088669 | 0.83 | CYP19A1 (0.49) | MTNR1AMTNR1BCYP19A1SLC6A2SLC6A4 | |
| SCHEMBL4773619 | 0.79 | CYP19A1 (0.53) | MTNR1AMTNR1BCYP19A1SLC6A2SLC6A4 | |
| SCHEMBL7192033 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BCYP19A1SLC6A2SLC6A4 | |
| SCHEMBL205557 | 0.78 | CYP19A1 (0.49) | CYP19A1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL8810284 | 0.77 | GABBR2 (0.53) | MTNR1AMTNR1BCYP19A1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | claimed |
| CN-100351245-C | Oxa- and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS OXFORD LTD (GB) | 2007-11-28 | — | — | CN | claimed |
| EP-1476438-B1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2007-04-18 | — | — | EP | claimed |
| CN-1747731-A | Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders | ALTANA PHARMA AG (DE) | 2006-03-15 | — | — | CN | claimed |
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2005-10-06 | — | — | US | claimed |
| CN-1646505-A | Oxa- and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS OXFORD LTD (GB) | 2005-07-27 | — | — | CN | claimed |
| WO-2004101537-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-11-25 | — | — | WO | claimed |
| EP-1476438-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2004-11-17 | — | — | EP | claimed |
| WO-2003070711-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2003-08-28 | — | — | WO | claimed |
| US-20030149084-A1 | Cytostatic agents | AYSCOUGH ANDREW PAUL (GB) | 2003-08-07 | — | — | US | claimed |
| JP-2002535272-A | — | — | 2002-10-22 | — | — | JP | claimed |
| EP-1146868-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-24 | — | — | EP | claimed |
| EP-1054861-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-29 | — | — | EP | claimed |
| WO-2000043001-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-07-27 | — | — | WO | claimed |
| WO-1999041232-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | claimed |
| WO-2020031897-A1 | POLYMERIZATION INITIATOR, CURABLE COMPOSITION, DENTAL MATERIAL, AND PREPARATION KIT FOR CURABLE COMPOSITION | 三井化学株式会社 | 2020-02-13 | — | — | WO | disclosed |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
| US-5071856-A | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| US-4886809-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0255134-A2 | Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149084-A1 | Cytostatic agents | MCTS1, NNMT, MMP12 | MTNR1A 1551/4885MTNR1B 1988/4885CYP19A1 1916/4885 |
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP9, TIMP3, MMP13 | MTNR1A 1097/4885MTNR1B 1182/4885CYP19A1 314/4885 |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | MTNR1A 797/4885MTNR1B 857/4885CYP19A1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.